StressCovidV1, PubMed, Corpus, bibRecord, 000772

Pandemic and seasonal influenza: therapeutic challenges.

Identifieur interne : 000772 ( PubMed/Corpus ); précédent : 000771; suivant : 000773

Pandemic and seasonal influenza: therapeutic challenges.

Auteurs : Matthew J. Memoli ; David M. Morens ; Jeffery K. Taubenberger

Source :

Drug discovery today [ 1359-6446 ] ; 2008.

RBID : pubmed:18598914

English descriptors

KwdEn :
- Antiviral Agents (therapeutic use), Cross Infection (complications), Cross Infection (drug therapy), Cross Infection (epidemiology), Disease Outbreaks, Humans, Influenza, Human (complications), Influenza, Human (epidemiology), Influenza, Human (therapy), Pharmacology, Clinical, Seasons.
MESH :
- chemical , therapeutic use : Antiviral Agents.
- complications : Cross Infection, Influenza, Human.
- drug therapy : Cross Infection.
- epidemiology : Cross Infection, Influenza, Human.
- therapy : Influenza, Human.
- Disease Outbreaks, Humans, Pharmacology, Clinical, Seasons.

Abstract

Influenza A viruses cause significant morbidity and mortality annually, and the threat of a pandemic underscores the need for new therapeutic strategies. Here, we briefly discuss novel antiviral agents under investigation, the limitations of current antiviral therapy and stress the importance of secondary bacterial infections in seasonal and pandemic influenza. Additionally, the lack of new antibiotics available to treat increasingly drug resistant organisms such as methicillin-resistant Staphylococcus aureus, pneumococci, Acinetobacter, extended spectrum beta-lactamase producing gram negative bacteria and Clostridium difficile is highlighted as an important component of influenza treatment and pandemic preparedness. Addressing these problems will require a multidisciplinary approach, which includes the development of novel antivirals and new antibiotics, as well as a better understanding of the role secondary infections play on the morbidity and mortality of influenza infection.

DOI: 10.1016/j.drudis.2008.03.024
PubMed: 18598914

Links to Exploration step

pubmed:18598914

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pandemic and seasonal influenza: therapeutic challenges.</title>
<author><name sortKey="Memoli, Matthew J" sort="Memoli, Matthew J" uniqKey="Memoli M" first="Matthew J" last="Memoli">Matthew J. Memoli</name>
<affiliation><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. memolim@niaid.nih.gov</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Morens, David M" sort="Morens, David M" uniqKey="Morens D" first="David M" last="Morens">David M. Morens</name>
</author>
<author><name sortKey="Taubenberger, Jeffery K" sort="Taubenberger, Jeffery K" uniqKey="Taubenberger J" first="Jeffery K" last="Taubenberger">Jeffery K. Taubenberger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18598914</idno>
<idno type="pmid">18598914</idno>
<idno type="doi">10.1016/j.drudis.2008.03.024</idno>
<idno type="wicri:Area/PubMed/Corpus">000772</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000772</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pandemic and seasonal influenza: therapeutic challenges.</title>
<author><name sortKey="Memoli, Matthew J" sort="Memoli, Matthew J" uniqKey="Memoli M" first="Matthew J" last="Memoli">Matthew J. Memoli</name>
<affiliation><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. memolim@niaid.nih.gov</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Morens, David M" sort="Morens, David M" uniqKey="Morens D" first="David M" last="Morens">David M. Morens</name>
</author>
<author><name sortKey="Taubenberger, Jeffery K" sort="Taubenberger, Jeffery K" uniqKey="Taubenberger J" first="Jeffery K" last="Taubenberger">Jeffery K. Taubenberger</name>
</author>
</analytic>
<series><title level="j">Drug discovery today</title>
<idno type="ISSN">1359-6446</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term>
<term>Cross Infection (complications)</term>
<term>Cross Infection (drug therapy)</term>
<term>Cross Infection (epidemiology)</term>
<term>Disease Outbreaks</term>
<term>Humans</term>
<term>Influenza, Human (complications)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (therapy)</term>
<term>Pharmacology, Clinical</term>
<term>Seasons</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cross Infection</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cross Infection</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cross Infection</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Disease Outbreaks</term>
<term>Humans</term>
<term>Pharmacology, Clinical</term>
<term>Seasons</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza A viruses cause significant morbidity and mortality annually, and the threat of a pandemic underscores the need for new therapeutic strategies. Here, we briefly discuss novel antiviral agents under investigation, the limitations of current antiviral therapy and stress the importance of secondary bacterial infections in seasonal and pandemic influenza. Additionally, the lack of new antibiotics available to treat increasingly drug resistant organisms such as methicillin-resistant Staphylococcus aureus, pneumococci, Acinetobacter, extended spectrum beta-lactamase producing gram negative bacteria and Clostridium difficile is highlighted as an important component of influenza treatment and pandemic preparedness. Addressing these problems will require a multidisciplinary approach, which includes the development of novel antivirals and new antibiotics, as well as a better understanding of the role secondary infections play on the morbidity and mortality of influenza infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18598914</PMID>
<DateCompleted><Year>2008</Year>
<Month>10</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>10</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1359-6446</ISSN>
<JournalIssue CitedMedium="Print"><Volume>13</Volume>
<Issue>13-14</Issue>
<PubDate><Year>2008</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Drug discovery today</Title>
<ISOAbbreviation>Drug Discov. Today</ISOAbbreviation>
</Journal>
<ArticleTitle>Pandemic and seasonal influenza: therapeutic challenges.</ArticleTitle>
<Pagination><MedlinePgn>590-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.drudis.2008.03.024</ELocationID>
<Abstract><AbstractText>Influenza A viruses cause significant morbidity and mortality annually, and the threat of a pandemic underscores the need for new therapeutic strategies. Here, we briefly discuss novel antiviral agents under investigation, the limitations of current antiviral therapy and stress the importance of secondary bacterial infections in seasonal and pandemic influenza. Additionally, the lack of new antibiotics available to treat increasingly drug resistant organisms such as methicillin-resistant Staphylococcus aureus, pneumococci, Acinetobacter, extended spectrum beta-lactamase producing gram negative bacteria and Clostridium difficile is highlighted as an important component of influenza treatment and pandemic preparedness. Addressing these problems will require a multidisciplinary approach, which includes the development of novel antivirals and new antibiotics, as well as a better understanding of the role secondary infections play on the morbidity and mortality of influenza infection.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Memoli</LastName>
<ForeName>Matthew J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. memolim@niaid.nih.gov</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morens</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Taubenberger</LastName>
<ForeName>Jeffery K</ForeName>
<Initials>JK</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>Z01 AI000995-01</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>Z99 AI999999</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2008</Year>
<Month>05</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Drug Discov Today</MedlineTA>
<NlmUniqueID>9604391</NlmUniqueID>
<ISSNLinking>1359-6446</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003428" MajorTopicYN="N">Cross Infection</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004196" MajorTopicYN="Y">Disease Outbreaks</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010601" MajorTopicYN="N">Pharmacology, Clinical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>71</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>01</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>03</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>03</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>7</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>10</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>7</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18598914</ArticleId>
<ArticleId IdType="pii">S1359-6446(08)00119-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.drudis.2008.03.024</ArticleId>
<ArticleId IdType="pmc">PMC2556034</ArticleId>
<ArticleId IdType="mid">NIHMS58877</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>JAMA. 2000 Feb 23;283(8):1016-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10697061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Pathol. 2008;3:499-522</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18039138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2000 Dec 14;343(24):1778-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11114318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2001 Apr 17;20(8):2078-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11296240</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull Hist Med. 2002 Spring;76(1):105-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11875246</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2002 Apr;46(4):977-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11897578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2003 Jan 8;289(2):179-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12517228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Nov 28;302(5650):1519-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14645836</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Feb 21;363(9409):617-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14987888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2004 May 1;38(9):1279-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15127341</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8682-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15173583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Aug 28-Sep 3;364(9436):759-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15337401</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 1971 Jun;127(6):1037-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5578560</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1985 Mar;27(3):309-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3888102</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1988 May;62(5):1508-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3282079</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Respir Infect. 1994 Sep;9(3):199-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7831542</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1999 Mar 10;281(10):901-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10078486</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1999 Jul 30;17 Suppl 1:S3-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10471173</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 1959 Jan;38(1 Part 2):213-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13620784</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Infect Control. 2004 Dec;32(8):470-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15573054</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2005 Jan 1;40(1):100-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15614698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2005 Jan 27;352(4):333-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15668219</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2005 Mar;49(3):981-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15728892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2005 Oct 1;366(9492):1175-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16198766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2005 Oct 20;437(7062):1108</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16228009</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2005 Dec 22;353(25):2667-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16371632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):3-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494709</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):15-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494711</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Feb 23;354(8):785-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16495389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2006;12(11):1339-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16611119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2006 Jun;12(6):894-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16707043</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2006 Jul 27;442(7101):448-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16642006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12121-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16880383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Nov 23;355(21):2174-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17124014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2006 Dec;80(24):11960-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17005658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2006 Nov 1;194 Suppl 2:S119-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17163384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2007 Jan;7(1):21-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17182341</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2007 Apr 1;195(7):1018-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17330793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2007 Apr 13;56(14):325-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17431376</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2007 May 9;297(18):2025-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17488968</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2007 Mar;3(3):e40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17335350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Respir Res. 2007;8:38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17509128</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2007 Jul 15;196(2):249-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17570112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Biol Evol. 2007 Aug;24(8):1811-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17522084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2007 Nov;76(2):186-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17719657</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem. 2007;14(21):2304-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17896978</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2007 Oct;132(4):1406; author reply 1406-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17934130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2007 Oct;132(4):1407; author reply 1407-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17934131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chest. 2007 Oct;132(4):1408; author reply 1408-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17934132</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cleve Clin J Med. 2007 Dec;74(12):889-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18183839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Jan 17;358(3):261-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18199865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 Jul;13(7):1061-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18214180</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 Sep;13(9):1348-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18252106</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 Oct;13(10):1512-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18258000</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Emerg Drugs. 2008 Mar;13(1):21-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18321146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2008 Mar;7(2):241-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18324892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Med. 2000;51:407-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10774473</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000772 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000772 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:18598914
   |texte=   Pandemic and seasonal influenza: therapeutic challenges.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:18598914" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a StressCovidV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021

	Serveur d'exploration Stress et Covid
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Stress et Covid

Pandemic and seasonal influenza: therapeutic challenges.

Pandemic and seasonal influenza: therapeutic challenges.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki